Syros Pharmaceuticals, Inc.: gross property, plant and equipment

What this measure means

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Exact concept: us-gaap:PropertyPlantAndEquipmentGross. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2015-12-31 to 2023-12-31. The SEC response was captured on 2026-09-21.

This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.

Selected filing history

Related financial histories

• Syros Pharmaceuticals, Inc.: total assets
• Syros Pharmaceuticals, Inc.: stockholders equity
• Syros Pharmaceuticals, Inc.: cash and cash equivalents
• Syros Pharmaceuticals, Inc.: net income or loss
• Syros Pharmaceuticals, Inc.: operating cash flow
• Syros Pharmaceuticals, Inc.: capital expenditure payments
• Syros Pharmaceuticals, Inc.: revenue
• Syros Pharmaceuticals, Inc.: contract revenue excluding tax
• Syros Pharmaceuticals, Inc.: financing cash flow
• Syros Pharmaceuticals, Inc.: investing cash flow
• Syros Pharmaceuticals, Inc.: retained earnings or deficit
• Syros Pharmaceuticals, Inc.: basic weighted-average shares
• Syros Pharmaceuticals, Inc.: diluted weighted-average shares
• Syros Pharmaceuticals, Inc.: basic earnings per share
• Syros Pharmaceuticals, Inc.: diluted earnings per share
• Syros Pharmaceuticals, Inc.: income tax expense or benefit
• Syros Pharmaceuticals, Inc.: net property, plant and equipment
• Syros Pharmaceuticals, Inc.: share-based compensation expense
• Syros Pharmaceuticals, Inc.: operating income or loss
• Syros Pharmaceuticals, Inc.: current assets
• Syros Pharmaceuticals, Inc.: interest expense
• Syros Pharmaceuticals, Inc.: current liabilities
• Syros Pharmaceuticals, Inc.: current accounts payable
• Syros Pharmaceuticals, Inc.: net current accounts receivable
• Syros Pharmaceuticals, Inc.: operating expenses
• Syros Pharmaceuticals, Inc.: research and development expense
• Syros Pharmaceuticals, Inc.: common shares outstanding
• Syros Pharmaceuticals, Inc.: cash including restricted cash
• Syros Pharmaceuticals, Inc.: accumulated other comprehensive income or loss
• Syros Pharmaceuticals, Inc.: operating lease right-of-use asset
• Syros Pharmaceuticals, Inc.: operating lease liability
• Syros Pharmaceuticals, Inc.: accumulated depreciation on property, plant and equipment
• Syros Pharmaceuticals, Inc.: other noncurrent assets
• Syros Pharmaceuticals, Inc.: prepaid expenses and other current assets
• Syros Pharmaceuticals, Inc.: net deferred tax assets
• Syros Pharmaceuticals, Inc.: profit or loss including noncontrolling interests
• Syros Pharmaceuticals, Inc.: comprehensive income or loss
• Syros Pharmaceuticals, Inc.: net income available to common stockholders
• Syros Pharmaceuticals, Inc.: general and administrative expense
• Syros Pharmaceuticals, Inc.: depreciation, depletion and amortization
• Syros Pharmaceuticals, Inc.: other nonoperating income or expense
• Syros Pharmaceuticals, Inc.: current income tax expense or benefit
• Syros Pharmaceuticals, Inc.: interest paid, net
• Syros Pharmaceuticals, Inc.: proceeds from issuing common stock
• Syros Pharmaceuticals, Inc.: operating lease payments
• Syros Pharmaceuticals, Inc.: change in accounts receivable
• Syros Pharmaceuticals, Inc.: change in accounts payable

Inspect the source

Entity

Syros Pharmaceuticals, Inc. / CIK 0001556263

Captured

2026-09-21T17:19:52.081Z

SEC response SHA-256

b38e30deae906481c51e5fcc32e3ef3c0aefc44173b9d7a37ce39e45d2ebaf1a

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001556263.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))